Scott Habig

Scott Habig joins Aurinia as Chief Commercial Officer with more than 20 years of global and U.S. sales and marketing experience and relevant expertise in Rheumatology and Lupus markets. A transformational leader and collaborator, Scott has an accomplished history of engaging and inspiring salesforces, creating patient-centric environments, and blending strategic leadership and forecasting abilities to exceed expectations and business goals. Over the past ten years, Scott has held numerous leadership roles at UCB, Inc and most recently was Head of Global SLE, maintaining full responsibility for pre-launch and commercial launch activities of a novel CD40 ligand currently in Phase III of clinical development for Systemic Lupus Erythematosus (SLE). His previous roles include Vice President, Sales at Human Genome Sciences, where he led the development and execution of organizational capabilities and infrastructure to support the company’s first sales team and led organizational and operational initiatives to guide the first major Lupus drug launch in more than 50 years. Prior to this role, Scott spent nine years at Centocor, Inc. where he led development and execution of sales and marketing strategies for one of the first biologic therapies approved for multiple autoimmune disorders. Under Scott’s sales and marketing leadership at Centocor, the company transformed a multimillion-dollar pipeline into a multibillion-dollar product. Scott received his B.A. from the University of Akron.